Merck, Keytruda
Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...
Merck's new formulation could help secure a larger share of Keytruda's sales after the cancer drug's U.S. patent expires in ...
Tuesday said its Phase 3 study evaluating subcutaneous Keytruda with Alteogen Inc.'s berahyaluronidase alfa in ...
I expect 10 companies to announce their annual increases in the second half of November. Click here for a detailed analysis.
The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant ...
Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
Merck KGaA on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by temporarily lower spending on drug ...
Merck KGaA posted earnings that topped estimates as its life science unit recovers from its post-pandemic slump alongside ...
The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...
The Rebecca Foundation, in collaboration with Merck Foundation, has presented 30 brilliant but needy girls with school ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback